Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GT Biopharma ( (GTBP) ) has provided an update.
On May 12, 2025, GT Biopharma, Inc. entered into a Securities Purchase Agreement with purchasers for the issuance and sale of Series L 10% Convertible Preferred Stock and accompanying warrants. The agreement was amended on May 21, 2025, to increase the number of shares and warrants, with a total stated value of $6,611,111.00 and a purchase price of $5,950,000.00. Additionally, the company filed a Certificate of Increase on May 22, 2025, to expand the shares of Series L Convertible Preferred Stock, reflecting strategic efforts to enhance capital structure and market presence.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutic products. The company specializes in oncology treatments, particularly targeting cancer therapeutics.
Average Trading Volume: 46,602
Technical Sentiment Signal: Sell
Current Market Cap: $7.47M
See more data about GTBP stock on TipRanks’ Stock Analysis page.